UBS has given Novo Nordisk a 'Neutral' rating and set a target price of 1100 Danish crowns.
According to analyst Jo Walton, the weight loss drug Wegovy is seeing an increase in prescriptions in the United States, indicating a positive trend in demand.
The commentary emphasizes the continued success of Wegovy in the market. This could impact investor sentiment as Novo Nordisk competes in the weight management treatments sector.